The Cost-Effectiveness of a Telemedicine Screening Program for Diabetic Retinopathy in New York City

References

• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:1–25.
   PubMedGoogle Scholar
• Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608–1622. doi:10.1016/j.ophtha.2018.04.007
   PubMed Web of Science ®Google Scholar
• Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:412–418. doi:10.2337/dc16-2641
   PubMed Web of Science ®Google Scholar
• Liu Y,Zupan NJ, Shiyanbola OO, et al. Factors influencing patient adherence with diabetic eye screening in rural communities: a qualitative study. PLoS One. 2018;13:e0206742.
   PubMed Web of Science ®Google Scholar
• Murchison AP, Hark L, Pizzi LT, et al. Non-adherence to eye care in people with diabetes. BMJ Open Diabetes Res Care. 2017;5:e000333. doi:10.1136/bmjdrc-2016-000333
   PubMed Web of Science ®Google Scholar
• Keenum Z, McGwin G, Witherspoon CD, et al. Patients’ adherence to recommended follow-up eye care after diabetic retinopathy screening in a publicly funded county clinic and factors associated with follow-up eye care use. JAMA Ophthalmol. 2016;134:1221–1228. doi:10.1001/jamaophthalmol.2016.3081
   PubMed Web of Science ®Google Scholar
• Thompson AC, Thompson MO, Young DL, et al. Barriers to follow-up and strategies to improve adherence to appointments for care of chronic eye diseases. Invest Ophthalmol Vis Sci. 2015;56:4324–4331. doi:10.1167/iovs.15-16444
   PubMed Web of Science ®Google Scholar
• Adriono G, Wang D, Octavianus C, Congdon N. Use of eye care services among diabetic patients in urban Indonesia. Arch Ophthalmol. 2011;129:930–935. doi:10.1001/archophthalmol.2011.147
   PubMedGoogle Scholar
• Ahmed J, Ward TP, Bursell S-E, et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care. 2006;29:2205–2209. doi:10.2337/dc06-0295
   PubMed Web of Science ®Google Scholar
• Ogunwole SM, Golden SH. Social determinants of health and structural inequities—root causes of diabetes disparities. Diabetes Care. 2021;44:11–13. doi:10.2337/dci20-0060
   PubMed Web of Science ®Google Scholar
• Kulshreshtha A, Goyal A, Dabhadkar K, Veledar E, Vaccarino V. Urban-rural differences in coronary heart disease mortality in the United States: 1999–2009. Public Health Rep. 2014;129:19–29. doi:10.1177/003335491412900105
   PubMed Web of Science ®Google Scholar
• Hamedani AG, VanderBeek BL, Willis AW. Blindness and visual impairment in the medicare population: disparities and association with hip fracture and neuropsychiatric outcomes. Ophthalmic Epidemiol. 2019;26:279–285. doi:10.1080/09286586.2019.1611879
   PubMed Web of Science ®Google Scholar
• Zambelli-Weiner A, Crews JE, Friedman DS. Disparities in adult vision health in the United States. Am J Ophthalmol. 2012;154:S23–S30.e1. doi:10.1016/j.ajo.2012.03.018
   PubMed Web of Science ®Google Scholar
• Wu WY, Jiang Q, Di Lonardo SS. Poorly controlled diabetes in New York city: mapping high-density neighborhoods. J Public Health Manag Pract JPHMP. 2018;24:69–74. doi:10.1097/PHH.0000000000000544
   PubMed Web of Science ®Google Scholar
• Farrell P, Barnaby S, Galarza T, et al. Population management of diabetes in a high-need urban community in the Bronx: the experience of Montefiore Medical Center. Diabetes Educ. 2013;39:515–522. doi:10.1177/0145721713487259
   PubMed Web of Science ®Google Scholar
• Mike EV, Laroche D. Preserving vision in the COVID-19 pandemic: focus on health equity. Clin Ophthalmol Auckl NZ. 2020;14:2073–2077. doi:10.2147/OPTH.S262586
   PubMed Web of Science ®Google Scholar
• Alroy KA, Crossa A, Dominianni C, et al. Population-based estimates of coronavirus disease 2019 (COVID-19)–like illness, COVID-19 illness, and rates of case ascertainment, hospitalizations, and deaths—noninstitutionalized New York city residents, March–April 2020. Clin. Infect. Dis. 2021;73:1707–1710. doi:10.1093/cid/ciab038
   PubMed Web of Science ®Google Scholar
• Byrne MM, Parker DF, Tannenbaum SL, et al. Cost of a community-based diabetic retinopathy screening program. Diabetes Care. 2014;37:e236–e237. doi:10.2337/dc14-0834
   PubMed Web of Science ®Google Scholar
• James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ. 2000;320:1627–1631. doi:10.1136/bmj.320.7250.1627
   PubMed Web of Science ®Google Scholar
• Silva PS, Cavallerano JD, Aiello LM, Aiello LP. Telemedicine and diabetic retinopathy: moving beyond retinal screening. Arch Ophthalmol. 2011;129:236–242. doi:10.1001/archophthalmol.2010.365
   PubMedGoogle Scholar
• Avidor D, Loewenstein A, Waisbourd M, Nutman A. Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. Cost Eff Resour Alloc CE. 2020;18:1–9.
   PubMed Web of Science ®Google Scholar
• Dehmer SP, Maciosek MV, LaFrance AB, Flottemesch TJ. Health benefits and cost-effectiveness of asymptomatic screening for hypertension and high cholesterol and aspirin counseling for primary prevention. Ann Fam Med. 2017;15:23–36. doi:10.1370/afm.2015
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324–330. doi:10.1016/S0002-9394(99)00146-4
   PubMed Web of Science ®Google Scholar
• Prieto L, Sacristán JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1(80):1–8.
   PubMedGoogle Scholar
• Brown GC, Brown MM, Chaudhry I, Stein JD. Opportunities to reduce potential bias in ophthalmic cost-utility analysis. JAMA Ophthalmol. 2021;139:389–397. doi:10.1001/jamaophthalmol.2020.6591
   PubMed Web of Science ®Google Scholar
• Garoon RB, Lin WV, Young AK, et al. Cost savings analysis for a diabetic retinopathy teleretinal screening program using an activity-based costing approach. Ophthalmol Retina. 2018;2:906–913. doi:10.1016/j.oret.2018.01.020
   PubMedGoogle Scholar
• Maberley D, Walker H, Koushik A, Cruess A. Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ Can Med Assoc J. 2003;168:160–164.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716–721. doi:10.1056/NEJM197703312961304
   PubMed Web of Science ®Google Scholar
• Shotliff K, Duncan G. Diabetic retinopathy: summary of grading and management criteria. Pract Diabetes Int. 2006;23:418–420. doi:10.1002/pdi.1029
   Google Scholar
• Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the pan-american collaborative retina study group at 24 months. Ophthalmology. 2009;116:1488–1497.e1. doi:10.1016/j.ophtha.2009.03.016
   PubMed Web of Science ®Google Scholar
• Wittenborn J, Rein D, Feagan CW, NORC at the University of Chicago. The economic burden of vision loss and eye disorders in the United States. Ophthalmology. 2013;120(9):1728–1735. doi:10.1016/j.ophtha.2013.01.068
   PubMed Web of Science ®Google Scholar
• ETDRS Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1 early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103:1796–1806. doi:10.1001/archopht.1985.01050120030015
   PubMedGoogle Scholar
• The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88:583–600.
   PubMed Web of Science ®Google Scholar
• Rossetti L, Digiuni M, Giovanni M, et al. Blindness and glaucoma: a multicenter data review from 7 academic eye clinics. PLoS One. 2015;10(8):e0136632. doi:10.1371/journal.pone.0136632
   PubMed Web of Science ®Google Scholar
• Shah SP, Gilbert CE, Razavi H, Turner EL, Lindfield RJ. Preoperative visual acuity among cataract surgery patients and countries’ state of development: a global study. Bull World Health Organ. 2011;89:749–756. doi:10.2471/BLT.10.080366
   PubMed Web of Science ®Google Scholar
• Firth SJ. The quality adjusted life year: a total-utility perspective. Camb Q Healthc Ethics CQ Int J Healthc Ethics Comm. 2018;27:284–294. doi:10.1017/S0963180117000615
   PubMed Web of Science ®Google Scholar
• Real FJ, Brown GC, Brown HC, Brown MM. The effect of comorbidities upon ocular and systemic health-related quality of life. Br J Ophthalmol. 2008;92:770–774. doi:10.1136/bjo.2007.127407
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, Hollands H, Landy J. Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol. 2002;86:8–11. doi:10.1136/bjo.86.1.8
   PubMed Web of Science ®Google Scholar
• Jani PD, Forbes L, Choudhury A, et al. Evaluation of diabetic retinal screening and factors for ophthalmology referral in a telemedicine network. JAMA Ophthalmol. 2017;135:706–714. doi:10.1001/jamaophthalmol.2017.1150
   PubMed Web of Science ®Google Scholar
• Mansberger SL, Gleitsmann K, Gardiner S, et al. comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: a randomized controlled trial. Telemed J E Health. 2013;19:942–948. doi:10.1089/tmj.2012.0313
   PubMed Web of Science ®Google Scholar
• Lee JC, Nguyen L, Hynan LS, Blomquist PH. Comparison of 1-field, 2-fields, and 3-fields fundus photography for detection and grading of diabetic retinopathy. J Diabetes Complications. 2019;33:107441. doi:10.1016/j.jdiacomp.2019.107441
   PubMed Web of Science ®Google Scholar
• Ullah W, Pathan SK, Panchal A, et al. Cost-effectiveness and diagnostic accuracy of telemedicine in macular disease and diabetic retinopathy. Medicine. 2020;99:e20306. doi:10.1097/MD.0000000000020306
   PubMed Web of Science ®Google Scholar
• Thomas S, Hodge W, Malvankar-Mehta M. The cost-effectiveness analysis of teleglaucoma screening device. PLoS One. 2015;10:e0137913. doi:10.1371/journal.pone.0137913
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797. doi:10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Kirkizlar E, Serban N, Sisson JA, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the veterans health administration. Ophthalmol. 2013;120:2604–2610. doi:10.1016/j.ophtha.2013.06.029
   PubMed Web of Science ®Google Scholar
• DeBuc DC. The role of retinal imaging and portable screening devices in tele-ophthalmology applications for diabetic retinopathy management. Curr Diab Rep. 2016;16(132). doi:10.1007/s11892-016-0827-2
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Busbee BG. Cost-utility analysis of cataract surgery in the United States for the year 2018. J Cataract Refract Surg. 2019;45:927–938. doi:10.1016/j.jcrs.2019.02.006
   PubMed Web of Science ®Google Scholar
• Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol Chic Ill 1960. 2012;130:497–505.
   PubMed Web of Science ®Google Scholar